Male subjects, healthy
Showing 1 - 25 of >10,000
Healthy Male Subjects Trial in Shanghai ([14C] Yiqibuvir)
Not yet recruiting
- Healthy Male Subjects
- [14C] Yiqibuvir
-
Shanghai, Shanghai, ChinaShanghai xuhui central hospital
Aug 16, 2023
Healthy Male Subjects Trial (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab
Not yet recruiting
- Healthy Male Subjects
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection
- Pembrolizumab injection
- (no location specified)
Oct 30, 2023
Healthy Male Subjects Trial in Lincoln (14C RPT193)
Not yet recruiting
- Healthy Male Subjects
- 14C RPT193
-
Lincoln, NebraskaCelerion
Oct 13, 2023
Healthy Male Subjects Trial in Brooklyn (Savolitinib, Fluvoxamine)
Not yet recruiting
- Healthy Male Subjects
-
Brooklyn, MarylandResearch Site
May 25, 2023
Healthy Male Trial in Beijing (Envafolimab with new manufacturing process, Envafolimab with old manufacturing process)
Not yet recruiting
- Healthy Male
- Envafolimab with new manufacturing process
- Envafolimab with old manufacturing process
-
Beijing, Beijing, ChinaBeijing Gaobo Boren Hosipital
May 9, 2023
Healthy Male Subjects Trial in Shanghai ([14C] Antaitavir Hasophate)
Completed
- Healthy Male Subjects
- [14C] Antaitavir Hasophate
-
Shanghai, Shanghai, ChinaShanghai xuhui central hospital
Jan 4, 2023
Phase 1 Study, Healthy Volunteers Trial in Beijing ([14C]DWP14012)
Active, not recruiting
- Phase 1 Study, Healthy Volunteers
-
Beijing, ChinaBeijing GoBroad Boren Hospital
May 11, 2023
This is a Phase Study Conducted in Healthy Volunteers, Osteoporosis Trial (Denosumab)
Not yet recruiting
- This is a Phase Study Conducted in Healthy Volunteers
- Osteoporosis
- Denosumab
- (no location specified)
May 17, 2023
Healthy Male Subjects Trial in Christchurch (Denosumab)
Recruiting
- Healthy Male Subjects
- Denosumab
-
Christchurch, Christchuch, New ZealandNZCR: New Zealand Clinical Research
Jan 24, 2023
Healthy Trial in Madison (Fadraciclib)
Active, not recruiting
- Healthy
-
Madison, WisconsinLabcorp Clinical Research Unit
Apr 5, 2023
Healthy Male Subjects Trial in Changsha (sintilimab (after the change), sintilimab (before the change))
Recruiting
- Healthy Male Subjects
- sintilimab (after the change)
- sintilimab (before the change)
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Dec 5, 2022
Breast Cancer, Nonsmall Cell Lung Cancer Trial in Beijing ([14C]GB491)
Completed
- Breast Cancer
- Nonsmall Cell Lung Cancer
-
Beijing, Beijing, ChinaBeijing GoBroad Boren Hospital
May 5, 2023
Immune System Disorder (Healthy Volunteer) Trial in Baltimore (Belumosudil mesylate, Placebo)
Completed
- Immune System Disorder (Healthy Volunteer)
- Belumosudil mesylate
- Placebo
-
Baltimore, MarylandInvestigational site
Jun 15, 2023
Healthy Subject Trial in Seongnam, Daejeon (CT-P41, US-licensed Prolia)
Completed
- Healthy Subject
- CT-P41
- US-licensed Prolia
-
Seongnam, Bundang-gu, Korea, Republic of
- +1 more
Sep 7, 2023
Healthy Male Subjects Trial (tafolecimab (a modified manufacturing process), tafolecimab (a original manufacturing process))
Not yet recruiting
- Healthy Male Subjects
- tafolecimab (a modified manufacturing process)
- tafolecimab (a original manufacturing process)
- (no location specified)
Mar 29, 2023
Hypertriglyceridemia Trial in Hellerup (DHA-NAT, Placebo)
Recruiting
- Hypertriglyceridemia
- DHA-NAT
- Placebo
-
Hellerup, DenmarkCenter for Clinical Metabolic Research, Herlev-Gentofte Hospital
Jul 11, 2023
Healthy Men Trial in Hefei (BAT1806 prefilled subcutaneous injection/RoActemra® (from EU))
Not yet recruiting
- Healthy Men
- BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
-
Hefei, Anhui, ChinaThe Second Affiliated Hospital of Anhui Medical University
Jul 27, 2023
Healthy Trial in Tel Aviv (Anti-human CCL24 mAb (CM-101), Placebo)
Completed
- Healthy
- Anti-human CCL24 monoclonal antibody (CM-101)
- Placebo
-
Tel Aviv, IsraelTel Aviv Sourasky Medical Center
Sep 7, 2023
Influenza, Human Trial (ZX-7101A 80mg)
Not yet recruiting
- Influenza, Human
- ZX-7101A 80mg
- (no location specified)
Feb 6, 2023
Healthy Trial (BI 1584862, Placebo)
Not yet recruiting
- Healthy
- BI 1584862
- Placebo
- (no location specified)
Dec 1, 2023
Healthy Trial in Berlin, Hamburg (LY06006 (Denosumab Biosimilar), US-Prolia (Denosumab), EU-Prolia)
Completed
- Healthy
- LY06006 (Denosumab Biosimilar)
- +2 more
-
Berlin, Germany
- +1 more
Oct 18, 2023